News Transactions under Novozymes’ stock buyback program Staff February 15, 2021 Please read the full announcement in the attached PDF Attachment 2021_07_Stock_Buybackprogram Iframe sync Post navigation Previous: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatientsNext: Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference More Stories Cancer Clinical Trial DNA Healthcare News Pharmaceutical Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China Staff December 19, 2025 Cancer Healthcare News Pharmaceutical Cosmos Health is Forcing the Market to Reframe the Conversation Staff December 19, 2025 Healthcare News Pharmaceutical 1933 Industries Issues Reminder to Debenture Holders Ahead of December 22 Conversion Deadline and Highlights Positive Industry Developments Staff December 19, 2025
